Aberrant p53 protein expression and function in a panel of hematopoietic cell lines with different p53 mutations

European Journal of Haematology

Volumn 82, Issue 4, 2009, Pages 301-307

  Kamihira, Shimeru ^a   Terada, Chiharu ^a   Sasaki, Daisuke ^a   Yanagihara, Katsunori ^a   Tsukasaki, Kunihiro ^a   Hasegawa, Hiroo ^a   Yamada, Yasuaki ^a  

^a NAGASAKI UNIVERSITY   (Japan)

Author keywords

Adult T cell leukemia; Haplo insufficiency; Hematologic cell line; Mutation; P53

Indexed keywords

AMINO ACID; NUTLIN 1; PROTEIN P53;

AMINO ACID SEQUENCE; ARTICLE; BINDING SITE; CELL LINE; CONTROLLED STUDY; DNA BINDING; HEMATOPOIETIC CELL; HUMAN; MUTATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; WILD TYPE;

BINDING SITES; CELL LINE; CELL LINE, TUMOR; DELTARETROVIRUS INFECTIONS; DNA MUTATIONAL ANALYSIS; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; GENES, P53; HUMANS; MUTATION; OPEN READING FRAMES; PROTEIN BIOSYNTHESIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; T-LYMPHOCYTES; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 61349199031     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2009.01211.x     Document Type: Article

References (24)

1. Lain S, Lane DP. Tumor suppressor genes. In : Knowles M, Selby P, eds. Introduction to the Cellular and Molecular Biology of Cancer. Oxford : Oxford Press, 2005 : 135 55.
2. Poeta ML, Manola J, Goldwasser MA, et al. TP53 mutations and survivin in squamous-cell carcinoma of the head and neck. N Eng J Med 2007 357 : 2552 61.
3. Quon KC, Berns A. Haplo-insufficiency? Let me count the way. Genes Dev 2001 2 : 113 23.
4. Soussi T, Asselain B, Hamroun D, Kato S, Ishioka C, Claustres M, Beroud V. Meta-analysis of the p53 mutation database for mutant p53 biological activity reveals a methodological bias in mutation detection. Clin Cancer Res 2006 12 : 62 9.
5. Thomas M, Kalita A, Labrcque S, Pim D, Banks L, Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Cell Mol Biol 1999 19 : 1029 100.
6. Concin N, Zeillinger C, Tong D, et al. Comparison of p53 mutational status with mRNA and protein expression in a panel of 24 human breast carcinoma cell lines. Breast Cancer Res Treat 2003 79 : 37 46.
7. Lynch LC, Milner J. Loss of one p53 allele results in four-fold reduction of p53 mRNA and protein: a basis for p53 haplo-insufficiency. Oncogene 2006 25 : 3463 70.
8. Russo A, Migliavacca M, Zanna I, et al. p53 Mutations in L3-loop zinc-binding domain, DNA-ploidy, and S phase fraction are independent prognosis indicators in colorectal cancer: a prospective study with a five-year follow-up. Cancer Epidemiol Biomarkers Prev 2002 11 : 1322 31.
9. Anensen N, Haaland I, D'Santos C, Van Belle W, Gjertsen BT. Proteomics of p53 in diagnostics and therapy of acute myeloid leukemia. Curr Pharm Biotechnol 2006 7 : 199 207.
10. Renneville A, Roumier C, Biggio V, Nibourel O, Boissel N, Fenaux P, Preudhomme C. Cooperating gene mutations in acute myeloid leukemia: a review of the literature. Leukemia 2008 22 : 915 31.
11. Tawara M, Hogerzeil SJ, Yamada Y, et al. Impact of p53 aberration on the progression of adult T-cell leukemia/lymphoma. Cancer Lett 2006 234 : 249 55.
12. Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway b small-molecule antagonists of MDM2. Science 2004 303 : 844 8.
13. Yamada Y, Sugawara K, Hata T, et al. Interleukin-15 (IL-15) can replace the IL-2 signal in IL-2-dependent adult T-cell leukemia (ATL) cell lines: expression of IL-15 receptor alpha on ATL cells. Blood 1998 91 : 4265 72.
14. Untergasser A, Nijveen H, Rao X, Bisseling T, Geurts R, Leunissen LKM. Primer3Plus, an enhanced web interface to Primer3. Nucleic Acids Res 2007 35 : 71 74. web service issue, doi
15. Hasegawa H, Yamada Y, Komiyama K, et al. Dihydroflavonol BB-1, an extract of natural plant Blumea balsamifera, abrogates TRAIL resistance in leukemia cells. Blood 2006 107 : 679 88.
16. Wada M, Bartram CR, Nakamura H, et al. Analysis of p53 mutations in a large series of lymphoid hematologic malignancies of childhood. Blood 1993 82 : 3163 9.
17. Hollstein M, Rice K, Greenblatt MS, Soussi T, Fuchs R, Sorlie T, Hovig E, Smith-Sorensen B, Montesano B, Harris CC. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res 1994 22 : 3551 5.
18. Prokocimer M, Unger R, Rennert HS, Rotter V, Rennert G. Pooled analysis of p53 mutations in hematological malignancies. Hum Mutat 1998 12 : 4 18.
19. Nelson HH, Wilkojmen M, Marsit CJ, Kelsey KT. TP53 mutation, allelism and survival in non-small cell lung cancer. Carcinogenesis 2005 26 : 1770 3.
20. Yatabe Y, Konishi H, Mitsudome T, Nakamura S, Takahashi T. Topographical distributions of allelic loss in individual non-small cell lung cancers. Am J Pathol 2000 157 : 985 93.
21. Baumbusch LO, Myhre S, Langerod A, Bergamaschi A, Geisler SB, Lonning PE, Deppert W, Dornreiter I, Borresen-Dale AL. Expression of full-length p53 and its isoform delta-p53 in breast carcinomas in relation to mutation status and clinical parameters. Mol Cancer 2006 5 : 47 http://www.molecular-cancer.com/ content/51/47.
22. Yins Y, Charles W, Stephenst M, Lucianis G, Fahraeuss R. p53 stability and activity is regulated by Mdm2-mediated induction of alternative p53 translation products. Nat Cell Biol 2002 4 : 462 7.
23. Mills AA. p53: link to the past, bridge to the future. Genes Dev 2005 19 : 2091 9.
24. Walker DR, Bond JP, Tarone RE, Harris CC, Makalowski W, Boguski MS, Greenblatt MS. Evolutionary conservation and somatic mutation hotspot maps of p53: correlation with p53 protein structural and functional features. Oncogene 1999 19 : 211 8.